No CrossRef data available.
Published online by Cambridge University Press: 01 September 2022
Altered DNA methylation in the FK506 binding protein 5 (FKBP5) gene has been shown to regulate stress response, which may serve as a biomarker of depression and a promising candidate for explaining sexual differences. However, there is no consistent conclusion so far.
The present study aimed to test the associations of FKBP5 DNA methylation with depressive symptoms and whether these associations were influenced by sex.
A nested case-control study comprising 87 cases and 151 controls was conducted in South China from January 2019 and December 2019. Peripheral blood for DNA extraction and DNA methylation analysis of FKBP5 gene promoter was collected, and severity of depressive symptoms was assessed at baseline and after one year follow-up.
Compared to healthy controls, lower methylation percentage of FKBP5-12 CpG 1 was observed in adolescents with depressive symptoms after adjusting covariates (case: 0.94 ± 2.00, control: 0.47 ± 0.92; F = 5.41, P = 0.021). In addition, hypomethylation of FKBP5 CpG sites was not an independent risk factor for depressive symptoms after adjustment for environmental stress factors (P > 0.05). No significant sex differences were found in the association of FKBP5 gene methylation with depressive symptoms.
Lower levels of FKBP5 methylation were found in adolescents with depressive symptoms. Our study supported that the epigenetic factors did not act alone in the development of depressive symptoms. Taken together, these findings contribute to a better understanding of complex mechanisms of gene-environment interactions involved in depression.
No significant relationships.
Comments
No Comments have been published for this article.